Editas Medicine, Inc. (EDIT) is a Biotechnology company in the Healthcare sector, currently trading at $3.39. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is EDIT = $6 (+77% upside).
Valuation: EDIT trades at a trailing Price-to-Earnings (P/E) of -1.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.17.
Financials: revenue is $41M, +87.7%/yr average growth. Net income is $160M (loss), growing at +0.9%/yr. Net profit margin is -395% (negative). Gross margin is 100% (+32.1 pp trend).
Balance sheet: total debt is $77M against $27M equity (Debt-to-Equity (D/E) ratio 2.81, leveraged). Current ratio is 3.54 (strong liquidity). Debt-to-assets is 41.1%. Total assets: $187M.
Analyst outlook: 14 / 25 analysts rate EDIT as buy (56%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 73/100 (Pass), Past 0/100 (Fail), Health 33/100 (Fail), Moat 50/100 (Partial), Future 64/100 (Pass), Income 10/100 (Fail).
